Treatment evaluation of acute stroke for using in regenerative cell elements (TREASURE) trial: Rationale and design

摘要

Rationale MultiStem (R) (HLM051) is one of the promising allogenic cell products for acute ischemic stroke with strong evidence. A previous phase 2 randomized, double-blind, placebo-controlled, multicenter dose-escalation trial showed the safety of MultiStem (R) for acute ischemic stroke, with a time window beyond that of rt-PA and endovascular thrombectomy. We aim to obtain stronger evidence and to show the efficacy of the MultiStem (R) for treatment of ischemic stroke.